BioCentury
ARTICLE | Clinical News

CellSearch Circulating Tumor Cell Kit diagnostic data

June 25, 2012 7:00 AM UTC

Researchers at the University of Texas MD Anderson Cancer Center reported data from 302 chemotherapy-naïve patients with stage I-III non-metastatic operable breast cancer showing that detection of >=1 CTC as measured by Veridex LLC's CellSearch Circulating Tumor Cell Kit predicted reductions in both PFS and OS at a median follow-up of 35 months. Specifically, in 73 patients with >=1 CTC, 2-year PFS and OS rates were 87% and 94%, respectively, vs. 99% and 99% in patients with no CTCs (n=229; p=0.005 and p=0.01, respectively). Furthermore, in 16 patients with >=3 CTCs, 2-year PFS and OS rates were 69% and 81%, respectively, vs. 97% and 99% in patients with <3 CTCs (n=286; p<0.0001 for both). Data were published in The Lancet Oncology. ...